CDC42BPA — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sr-3677 (SCHEMBL453528)	0.77	5/20
Rosoxacin (SCHEMBL135645)	0.49	4/20
SCHEMBL154683	0.47	4/20
SCHEMBL363119	0.44	4/20
SCHEMBL363855	0.36	4/20
SCHEMBL364346	0.36	4/20
SCHEMBL95142	1.00	3/20
Ucn-01 (SCHEMBL259162)	1.00	3/20
SCHEMBL94964	0.79	3/20
SCHEMBL171201	0.69	3/20
SCHEMBL363116	0.39	3/20
SCHEMBL369534	0.39	3/20
SCHEMBL369535	0.39	3/20
SCHEMBL361993	0.38	3/20
SCHEMBL362642	0.37	3/20
SCHEMBL363842	0.37	3/20
SCHEMBL369687	0.37	3/20
SCHEMBL369688	0.37	3/20
SCHEMBL363521	0.36	3/20
SCHEMBL364544	0.35	3/20

Clinical trials — most relevant to CDC42BPA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cetuximab in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome	PHASE1	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Immune Cell Response to Stimuli	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Role of Chemokine and Chemokine Receptor in Psoriasis	nan	WITHDRAWN
Identification of an Asthma Susceptibility Gene on 3P	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDC42BPA binder may also engage these)

Protein	Name	Similarity
O54874	—	1.000	O54874 →
Q3UU96	—	1.000	Q3UU96 →
CDC42BPB	Serine/threonine-protein kinase MRCK beta	1.000	landscape →
Q7TT50	—	1.000	Q7TT50 →
Q28021	—	1.000	Q28021 →
Q62868	—	1.000	Q62868 →
P70336	—	1.000	P70336 →
M3TYT0	—	1.000	M3TYT0 →
Q7TT49	—	0.999	Q7TT49 →
ROCK2	Rho-associated protein kinase 2	0.998	landscape →
A7MD70	—	0.998	A7MD70 →
Q9W1B0	—	0.998	Q9W1B0 →
Q08DR9	—	0.996	Q08DR9 →
Q6NRW2	—	0.996	Q6NRW2 →
Q5BJF6	—	0.996	Q5BJF6 →
Q6ZU80	—	0.996	Q6ZU80 →
A8WVU9	—	0.996	A8WVU9 →
Q5ZKK5	—	0.996	Q5ZKK5 →
F1NBT0	—	0.995	F1NBT0 →
Q8TDM6	—	0.995	Q8TDM6 →
P70335	—	0.995	P70335 →
Q9C099	—	0.995	Q9C099 →
A5WW21	—	0.995	A5WW21 →
Q9UJC3	—	0.995	Q9UJC3 →
Q7YS99	—	0.995	Q7YS99 →
Q6NRC9	—	0.994	Q6NRC9 →
ROCK1	Rho-associated protein kinase 1	0.994	landscape →
Q6P3P1	—	0.994	Q6P3P1 →
O77819	—	0.994	O77819 →
P85120	—	0.993	P85120 →